Even though rapamycin is only one of four agents used in this treatment protocol, it will be important to test whether neuroblastoma patients with DDX1-MYCN amplifications respond better to RIST than neuroblastoma patients without such coamplifications. Here, DDX1 is linked to neuroblastoma.